A trial of extended-release niacin (Niaspan, Abbott) given in addition to statin therapy in patients with a history of cardiovascular disease, high triglycerides, and low levels of HDL cholesterol has been halted prematurely, 18 months ahead of schedule, because niacin offered no additional benefits in this patient population.Oops.
There was also a small, unexplained increase in ischemic stroke in the high-dose, extended-release niacin group, in the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH) study, according to a statement from the National Heart Lung and Blood Institute (NHLBI), which sponsored it.
Fitness Watch is your site for making sense of fitness advice.
"Truth" has a shelf life.
The shelf life of "truth" is very short in the domains of fitness, health and well-being.
The reason is that so much of what we are told is "true" is really baseless.
At Fitness Watch we separate fitness information from fitness noise.
Friday, May 27, 2011
NIH Pulls Plug on AIM-HIGH Trial With Niacin
Still think they have any idea of what a safe supplement is?
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.